Suppr超能文献

含氮杂环化合物作为治疗癌症的受体酪氨酸激酶抑制剂的研究进展:生物活性与构效关系

Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.

作者信息

Taruneshwar Jha Keshav, Shome Abhimannu, Chawla Pooja A

机构信息

Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab 142001, India.

Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab 142001, India.

出版信息

Bioorg Chem. 2023 Sep;138:106680. doi: 10.1016/j.bioorg.2023.106680. Epub 2023 Jun 17.

Abstract

Erratic cell proliferation is the initial symptom of cancer, which can eventually metastasize to other organs. Before cancer becomes metastatic, its spread is triggered by pro-angiogenic factors including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), Platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and Platelet Factor (PF4), all of which are part of receptor tyrosine kinase (RTK) family. Receptor tyrosine kinases (RTKs) are cell-surface proteins and aresignaling enzymes that transfer ATP-phosphate to tyrosine residue substrates. Important biological processes like proliferation, differentiation, motility, and cell-cycle regulation are all possessedby these proteins. Unusual RTK expression is typically associated with cell growth abnormalities, which is linked to tumor acquisition, angiogenesis, and cancer progression. In addition to the already available medications, numerous other heterocyclic are being studied for their potential action against a variety of cancers. In the fight against cancer, in particular, these heterocycles have been used for their dynamic core scaffold and their inherent adaptability. In this review article, we have compiled last five years research work including nitrogen containing heterocycles that have targeted RTK. Herein, the SAR and activity of various compounds containing diverse heterocyclic (pyrimidine, indole, pyridine, pyrazole, benzimidazole, and pyrrole) scaffolds are discussed, and they may prove useful in the future for designing new leads against RTKs. Our focus in this manuscript is to comprehensively review the latest research on the biological activity and structural activity relationship of nitrogen compounds as RTK inhibitors. We believe that this may be an important contribution to the field, as it can help guide future research efforts and facilitate the development of more effective cancer therapies.

摘要

细胞异常增殖是癌症的初始症状,最终可能会转移到其他器官。在癌症发生转移之前,其扩散是由促血管生成因子触发的,这些因子包括血管内皮生长因子受体(VEGFR)、表皮生长因子受体(EGFR)、血小板衍生生长因子受体(PDGFR)、成纤维细胞生长因子受体(FGFR)和血小板因子(PF4),它们都是受体酪氨酸激酶(RTK)家族的一部分。受体酪氨酸激酶(RTKs)是细胞表面蛋白,是将ATP磷酸基团转移到酪氨酸残基底物上的信号酶。这些蛋白具有增殖、分化、运动和细胞周期调控等重要生物学过程。RTK异常表达通常与细胞生长异常有关,而细胞生长异常与肿瘤的发生、血管生成和癌症进展相关。除了现有的药物外,许多其他杂环化合物正在被研究其对多种癌症的潜在作用。特别是在抗癌斗争中,这些杂环化合物因其动态核心骨架和固有的适应性而被使用。在这篇综述文章中,我们汇总了过去五年针对RTK的含氮杂环化合物的研究工作。本文讨论了各种含有不同杂环(嘧啶、吲哚、吡啶、吡唑、苯并咪唑和吡咯)骨架的化合物的构效关系和活性,它们可能在未来设计针对RTKs的新先导化合物中发挥作用。我们在本手稿中的重点是全面综述含氮化合物作为RTK抑制剂的生物活性和构效关系的最新研究。我们相信这可能是该领域的一项重要贡献,因为它可以帮助指导未来的研究工作,并促进更有效的癌症治疗方法的开发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验